• 1
    Li CY, Sung FC. A review of the healthy worker effect in occupational epidemiology. Occup Med (Lond) 1999; 49: 2259.
  • 2
    Brunner R, Dunbar-Jacob J, Leboff MS, Granek I, Bowen D, Snetselaar LG, et al. Predictors of adherence in the Women's Health Initiative Calcium and Vitamin D Trial. Behav Med 2009; 34: 14555.
  • 3
    Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15.
  • 4
    Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980; 303: 103841.
  • 5
    Curtis JR, Larson JC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, et al. Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. Med Care 2011; 49: 42735.
  • 6
    Curtis JR, Delzell E, Chen L, Black D, Ensrud K, Judd S, et al. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the Fracture Intervention Trial. J Bone Miner Res 2011; 26: 6838.
  • 7
    Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010; 21: 194351.
  • 8
    Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122 Suppl: S313.
  • 9
    Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. The benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008; 23: 143541.
  • 10
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 91520.
  • 11
    Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin receptor uptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351: 13037.
  • 12
    Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167: 12405.
  • 13
    MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148: 197213.
  • 14
    Wu Q, Bencaz AF, Hentz JG, Crowell MD. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int 2012; 23: 36575.
  • 15
    Solomon DH, Mogun H, Garneau K, Fischer MA. Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res 2011; 26: 15617.
  • 16
    Gagne JJ, Patrick AR, Mogun H, Solomon DH. Antidepressants and fracture risk in older adults: a comparative safety analysis. Clin Pharmacol Ther 2011; 89: 8807.
  • 17
    Rejnmark L, Vestergaard P, Mosekilde L. Treatment with β-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006; 24: 5819.
  • 18
    Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005; 11: 44957.
  • 19
    Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 74: 12935.
  • 20
    Curtis JR, Xi J, Westfall AO, Cheng H, Lyles K, Saag KG, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 2009; 47: 33441.
  • 21
    World Health Organization. Fracture risk assessment tool. 2012. URL:
  • 22
    Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from computerized Medicare files. J Clin Epidemiol 1992; 45: 70314.
  • 23
    Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG. Identification and validation of vertebral compression fractures using administrative claims data. Med Care 2009; 47: 6972.
  • 24
    Siris ES, Pasquale MK, Wang Y, Watts NB. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001–2008. J Bone Miner Res 2011; 26: 311.
  • 25
    Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007; 166: 34854.
  • 26
    Patrick AR, Shrank WH, Glynn RJ, Solomon DH, Dormuth CR, Avorn J, et al. The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. Value Health 2011; 14: 51320.
  • 27
    Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009; 119: 20517.
  • 28
    Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 17786.
  • 29
    Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int 2011; 22: 94354.
  • 30
    Yun H, Delzell E, Ensrud KE, Kilgore ML, Becker D, Morrisey MA, et al. Predicting hip and major osteoporotic fractures using administrative data. Arch Intern Med 2010; 170: 19402.